Medical Devices in radiation therapy (RT) undergo a complex process of Food and Drug Administration (FDA) Approval. Little is known about which processes within the RT medical device industry are most prone to events involving wrong dose, volume, or targeting in radiotherapy treatment. We carried out a retrospective analysis of the United States FDA Medical Device Recalls Database, looking specifically at recalls for products classified as “Accelerator, Linear, Medical” from 2010 to 2016. We excluded recall entries with insufficient information regarding the reason for recall, duplicate recall events involving the same vendor, and entries involving chemotherapy or other drug dosing. Each recall event was classified by modified Delphi method between 3 experts in safety (HL, DB, SE) according to product type, error category, and severity score. Severity score was assigned in accordance with American Association of Physicists in Medicine Task Group 100 methodology. Error categories include inconvenience, suboptimal plan or treatment, incorrect dose, volume, or targeting, and non-radiation injury risk. Any event that was felt to have the potential for incorrect dose, volume, or targeting was classified as such, under the assumption that a corrective action was not able to be performed. Variables investigated include product type, year, and FDA determined cause. Of note, our product type designation separated out all software errors into multiple subgroups indicative of which device was used, while the FDA classified all software errors together. Chi-squared analysis was used to identify factors prognostic of incorrect dose, volume, or targeting during RT delivery. We identified a total of 250 recall events between 2010 and 2016, with 166 eligible for analysis. Four events were excluded because they involved pharmaceutical errors, 38 were excluded as insufficient information, 42 were excluded as duplicate events. Error categories were assigned as inconvenience (6%), suboptimal plan (2.4%), wrong dose, volume, or targeting (74.45%), or non RT injury risk (17%). Of the recalls, Linacs were recalled (28%), Linac Control Software (20%), Patient Positioning Devices (18%), Oncology information system related (15%), and on board imaging (11%). The most common FDA determined causes for recalls were Software Design (42%) and Device Design (21%). 2011 had the highest number of recalls for linear accelerators compared to any other year. We found that recalls of product type Linac Control Software (P = 0.045) and FDA designated Software Design errors (P = 0.0014) significantly predicted for incorrect dose, targeting, or volume delivery. Review of this data shows that problems with the Linac-operating software may be more likely to lead to incorrect dose delivery. Manufacturers should focus on software design and subsequent improvements to minimize dose and targeting related errors to patients.